Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q3 2016 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了“公司先收到钱或绑定支付义务,然后才提供服务/交付”的现象,并且该现象正在增长,且管理层将其与公司下一步发展联系起来。 在记录中,管理层多次提到“deposits”(存款),特别是“current account deposits”和“time deposits”的增长。例如,在零售银行业务部分,提到“current account deposits grew 8% year-on-year and time deposits grew 10% year-on-year”。存款是客户将资金存入银行,银行尚未提供对应服务(贷款等),这属于客户提前将资金交给银行,银行之后用于放贷等。这符合“公司被提前支付”的概念。而且管理层明确表示这些存款增长是积极的,并提到“we have successfully continued to grow our retail base in both current account deposits and time deposits”。此外,在竞争优势部分,提到“Non-interest bearing deposits represent almost 25% of our total sources of funds with the highest market share of 23%”,说明存款是重要的资金来源,且是低成本资金。管理层将存款增长视为优势,并认为这有助于银行发展。 但需要确认:存款是否属于“counterparties paying in advance”?银行吸收存款,客户将钱存入银行,银行承诺支付利息,但银行并未立即提供等值服务,而是将存款用于贷款等。这类似于客户提前将资金交给银行,银行之后通过贷款等产生收益。但存款是银行的核心业务,并非特定项目的预付款。然而,从广义上讲,存款是客户将资金委托给银行,银行尚未提供对应服务(如贷款),但银行会支付利息。这更像是银行借入资金,而非客户为购买银行服务而预付。但银行的主要业务是吸收存款和发放贷款,存款是银行资金来源,客户存款并非为购买银行服务而预付,而是为了安全或利息。因此,可能不符合“公司被提前支付”的定义,因为存款不是客户为购买银行产品而支付的款项,而是银行负债。 更关键的是,管理层是否将存款增长与公司下一步发展联系起来?在记录中,管理层提到存款增长是“we have successfully continued to grow our retail base”,但并未明确说存款增长为公司的扩张提供资金或降低资本需求。实际上,存款是银行日常运营的一部分,并非特定项目的预付款。 另外,管理层还提到“we have the best funding structure in the industry”和“low cost of funds”,但并未说存款增长是“counterparties financing the company's next stage”。存款是银行常规业务,并非客户为获得未来服务而提前支付。 因此,我认为这不属于“公司被提前支付”的现象。管理层没有描述客户为购买银行服务而提前付款,而是银行吸收存款作为资金来源,这是银行常规运营。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.